1
|
Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K. [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. Pathologie (Heidelb) 2024; 45:51-58. [PMID: 38170268 PMCID: PMC10827825 DOI: 10.1007/s00292-023-01215-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/09/2023] [Indexed: 01/05/2024]
Abstract
As a result of the high approval dynamics and the growing number of immuno-oncological therapy concepts, the complexity of therapy decisions and control in the area of carcinomas of the esophagus, gastroesophageal junction and stomach is constantly increasing. Since the treatment indication for PD‑1 inhibitors that are currently approved in the European Union is often linked to the expression of PD-L1 (programmed cell death-ligand 1), the evaluation of tissue-based predictive markers by the pathologist is of crucial importance for treatment stratification. Even though the immunohistochemical analysis of the PD-L1 expression status is one of the best studied, therapy-relevant biomarkers for an immuno-oncological treatment, due to the high heterogeneity of carcinomas of the upper gastrointestinal tract, there are challenges in daily clinical diagnostic work with regard to implementation, standardization and interpretation of testing. An interdisciplinary group of experts from Germany has taken a position on relevant questions from daily pathological and clinical practice, which concern the starting material, quality-assured testing and the interpretation of pathological findings, and has developed recommendations for structured reporting.
Collapse
Affiliation(s)
- G Baretton
- Institut für Pathologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
| | - F Lordick
- Medizinische Klinik II (Onkologie, Gastroenterologie, Hepatologie und Pneumologie) und Universitäres Krebszentrum Leipzig, Universitätsmedizin Leipzig, Leipzig, Deutschland.
| | - T Gaiser
- PATHOLOGIE SPEYER Gemeinschaftspraxis GbR, Speyer, Deutschland
| | - R Hofheinz
- Universitätsmedizin Mannheim, Mannheim, Deutschland
| | - D Horst
- Institut für Pathologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland
| | - S Lorenzen
- III. Medizinische Klinik, Klinikum rechts der Isar, München, Deutschland
| | - M Möhler
- I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz, Mainz, Deutschland
| | - C Röcken
- Institut für Pathologie, Christian-Albrechts-Universität, Kiel, Deutschland
| | - P Schirmacher
- Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - M Stahl
- Klinik für Internistische Onkologie & Onkologische Palliativmedizin, KEM | Evang. Kliniken Essen-Mitte, Evang. Huyssens-Stiftung Essen-Huttrop, Essen, Deutschland
| | - P Thuss-Patience
- Charité Centrum Tumormedizin CC14, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Deutschland
| | - K Tiemann
- Institut für Hämatopathologie, Hamburg, Deutschland
| |
Collapse
|
2
|
Al-Batran SE, Götze T, Dechow T, Goekkurt E, Algül H, Decker T, Hegewisch Becker S, Hofheinz R, Möhler M, Stahl M, Thuss-Patience P, Herzer S, Pauligk C, Lorenzen S. 1499TiP FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – The phase II/III RAMIRIS study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag G, Luley K, Folprecht G, Probst S, Thuss-Patience P, Trojan J, Koenigsmann M, Lindig U, Pohl M, Kasper S, Möhler M, Goetze T, Schuler M, Jaeger E, Hofheinz R. Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Porschen R, Buck A, Fischbach W, Gockel I, Görling U, Grenacher L, Hollerbach S, Hölscher A, Körber J, Messmann H, Meyer HJ, Miehlke S, Möhler M, Nöthlings U, Pech U, Schmidberger H, Schmidt M, Stahl M, Stuschke M, Thuss-Patience P, Trojan J, Vanhoefer U, Weimann A, Wenz F, Wullstein C. [Not Available]. Z Gastroenterol 2015; 53:1288-347. [PMID: 26562403 DOI: 10.1055/s-0041-107381] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- R Porschen
- Klinik für Innere Medizin, Klinikum Bremen-Ost
| | - A Buck
- Klinik für Nuklearmedizin, Universitätsklinikum Würzburg
| | - W Fischbach
- Medizinische Klinik II, Klinikum Aschaffenburg
| | - I Gockel
- Klinik für Allgemein- und Abdominalchirurgie, Universitätsklinik Leipzig
| | - U Görling
- Charité Comprehensive Cancer Center, Psychoonkologie, Charité Campus Mitte, Berlin
| | - L Grenacher
- Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Heidelberg
| | - S Hollerbach
- Klinik für Innere Medizin, Allgemeines Krankenhaus Celle
| | - A Hölscher
- Klinik für Allgemein-, Viszeral- und Tumorchrirurgie, Universitätsklinik Köln
| | | | - H Messmann
- III. Medizinische Klinik, Klinikum Augsburg
| | - H J Meyer
- Deutsche Gesellschaft für Chirurgie, Berlin
| | - S Miehlke
- Magen-Darm-Zentrum, Hamburg-Eppendorf
| | - M Möhler
- I. Medizinische Klinik, Universitätsklinikum Mainz
| | - U Nöthlings
- Institut für Ernährungs- und Lebensmittelwissenschaften, Rheinische Friedrich-Wilhelms-Universität Bonn
| | - U Pech
- Klinik für Gastroenterolgie und Interventionelle Endoskopie, Krankenhaus Barmherzige Brüder Regensburg
| | - H Schmidberger
- Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Mainz
| | - M Schmidt
- Klinik für Nuklearmedizin, Universitätsklinik Köln
| | - M Stahl
- Klinik für Internistische Onkologie und Hämatologie, Klinik Essen-Mitte
| | - M Stuschke
- Klinik für Strahlentherapie, Universitätsklinikum Essen
| | - P Thuss-Patience
- Klinik für Hämatologie und Onkologie, Charité Campus Virchow Klinikum, Berlin
| | - J Trojan
- Medizinische Klinik I, Universitätsklinikum Frankfurt
| | - U Vanhoefer
- Zentrum für Innere Medizin, Marienkrankenhaus Hamburg
| | - A Weimann
- Klinik für Allgemein- und Viszeralchirurgie, Klinik St.-Georg, Leipzig
| | - F Wenz
- Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim
| | - C Wullstein
- Klinik für Allgemein- Viszeral und Minimalinvasive Chirurgie, Helios Klinikum Krefeld
| |
Collapse
|
5
|
Heinemann V, Modest D, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen C, Möhler M, Jagenburg A, Stintzing S. Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu193.30] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ. [Diagnosis of and therapy for hepatocellular carcinoma]. Z Gastroenterol 2013; 51:1269-326. [PMID: 24243572 PMCID: PMC6318804 DOI: 10.1055/s-0033-1355841] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The interdisciplinary guidelines at the S3 level on the diagnosis of and therapy for hepatocellular carcinoma (HCC) constitute an evidence- and consensus-based instrument that is aimed at improving the diagnosis of and therapy for HCC since these are very challenging tasks. The purpose of the guidelines is to offer the patient (with suspected or confirmed HCC) adequate, scientifically based and up-to-date procedures in diagnosis, therapy and rehabilitation. This holds not only for locally limited or focally advanced disease but also for the existence of recurrences or distant metastases. Besides making a contribution to an appropriate health-care service, the guidelines should also provide the foundation for an individually adapted, high-quality therapy. The explanatory background texts should also enable non-specialist but responsible colleagues to give sound advice to their patients concerning specialist procedures, side effects and results. In the medium and long-term this should reduce the morbidity and mortality of patients with HCC and improve their quality of life.
Collapse
|
7
|
Kiesslich R, Möhler M, Hansen T, Galle P, Lang H, Gockel I. Diagnostik und Therapie des Ösophaguskarzinoms. Internist (Berl) 2012; 53:1315-27; quiz 1328-9. [DOI: 10.1007/s00108-012-3128-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
8
|
Meyer HJ, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke H, Möhler M. [Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg 2012; 83:31-7. [PMID: 22127381 DOI: 10.1007/s00104-011-2149-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The current S3 guidelines on the diagnosis and treatment of gastric carcinoma including those of the esophagogastric junction describe optimal clinical practice based on a high level of evidence and expert consensus from different medical disciplines. Endoscopy and performance of multiple biopsies is the standard approach to detect malignant tumors in the upper gastrointestinal tract. Further diagnostic procedures are necessary to evaluate the tumor stage. With the exception of mucosal carcinomas, surgical therapy is the cornerstone of curative treatment in all potentially resectable stages. In locally advanced carcinomas perioperative chemotherapy should be carried out and in high-seated tumors preoperative radiochemotherapy might be an alternative option. Palliative surgical resection should be avoided in disseminated asymptomatic stages. In a palliative situation complications of the tumor should primarily be treated by interventional or conservative procedures.
Collapse
Affiliation(s)
- H-J Meyer
- Klinik für Allgemein und Viszeralchirurgie, Städtisches Klinikum Solingen gGmbH, Gotenstraße 1, 42653, Solingen, Deutschland.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Möhler M, Siveke JT, Schmid RM. [Gastric cancer - what's new?]. Dtsch Med Wochenschr 2011; 136:2492-5. [PMID: 22109584 DOI: 10.1055/s-0031-1297275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Affiliation(s)
- M Möhler
- I. Medizinische Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität, Langenbeckstr.1, 55101 Mainz.
| | | | | |
Collapse
|
10
|
Dünschede F, Will L, von Langsdorf C, Möhler M, Galle PR, Otto G, Vahl CF, Junginger T. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res 2010; 44:209-13. [PMID: 20571276 DOI: 10.1159/000313532] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2009] [Accepted: 04/13/2010] [Indexed: 12/15/2022]
Abstract
AIM Patients were analyzed who underwent treatment of liver metastases from pancreatic cancer. METHODS Selection criteria were the possibility of R0 resection of the primary and/or the liver metastases, no other sites of metastases, and the presentation of liver metastases. A comparison of treatment by surgery versus chemotherapy regarding overall survival and disease-free interval was performed. RESULTS Between 1996 and 2008, a total number of 23 patients were retrospectively identified from a prospective database of 193 cases of pancreatic cancer. In 14 cases, liver metastases were found simultaneously, and in 9 cases metachronously, fulfilling the abovementioned selection criteria. Of these, 13 patients underwent surgery and 10 were treated by gemcitabine. There were no differences in survival in patients with synchronous liver metastases of pancreatic cancer treated by resection of the primary combined with partial hepatectomy versus treatment by gemcitabine (8 vs. 11 months). In patients with metachronous liver metastases, the median survival was increased after liver resection compared to patients who were treated with gemcitabine (31 vs. 11 months). CONCLUSIONS Simultaneous resection of pancreatic cancer and liver metastases cannot be recommended. Resection of metachronous liver metastases of pancreatic cancer seems to improve survival in highly selected patients.
Collapse
Affiliation(s)
- F Dünschede
- Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital, Mainz, Germany. Duenschede @ htg.klinik.uni-mainz.de
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Schimanski CC, Möhler M, Zimmermann T, Gockel I, Lang H, Arbogast R, Jäger D, Galle PR, Berger MR. [Detection of hepatic micrometastases in the context of adjuvant chemotherapy and surgery for hepatic metastases]. Dtsch Med Wochenschr 2010; 135:1078-82. [PMID: 20486059 DOI: 10.1055/s-0030-1253703] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Colorectal cancer is one of the three most frequent malignancies in humans. Survival is mainly determined by local recurrence, lymphatic and hematogenous dissemination. Primary liver resection for metastases is possible in ~20-25% of patients with hepatic metastases and results in a 50% recurrence rate within 23 months. The five-year survival without treatment in patients with UICC stage IV is only 5%, the mean survival 6-9 months. As a result of promising developments in chemotherapy and targeted therapies in the last decade, the mean survival rate has significantly improved to over more than two years. Furthermore, the use of polychemotherapy in combination with anti-angiogenic and anti-proliferative biologicals has resulted in a significant increase of secondary resectability of liver metastases. Despite of a R0-resection (i.e. resection with clear margins) of liver metastases, only 30% of patients remain free of recurrence in the long-term. Prognostic scores are used for optimal patient selection, e.g. the Fong-Score. Resection is often limited by a high number of recurrences: intrahepatic micrometastases and disseminated tumor cells (DTC) are suspected as the cause of their development. In this connection the load of disseminated tumor cells correlates significantly with the survival and recurrence rate after resection. These micrometastases are targets in current adjuvant treatment studies (e.g. MT 201) by using anti-EpCam antibodies. The detection of DTC can supplement the previously used scores and represents the indication for an adjuvant antibody-based treatment (e.g. anti-EpCam) in the context of clinical trials.
Collapse
Affiliation(s)
- C C Schimanski
- I. Medizinische Klinik und Poliklinik, Universitätsmedizin, Johannes Gutenberg Universität Mainz. 1-med.klinik.uni-mainz.de
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Goekkurt E, Al-Batran S, Obermann L, Pauligk C, Homann N, Hartmann J, Möhler M, Hofheinz R, Ehninger G, Stoehlmacher J. 1111 Pharmacogenetics of peripheral neuropathy in elderly patients (> 65years) with advanced gastric cancer receiving oxaliplatin based chemotherapy within a randomized phase II study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70404-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Möhler M, Mueller A, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle P, Kanzler S. 6579 Cetuximab with Irinotecan/Folinic Acid/5-FU as first-line treatment in advanced gastric cancer: a prospective multi-center phase II study and additional biomarkers of the Arbeitsgemeinschaft Internistische Onkologie. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71300-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
14
|
Harder J, Hofheinz R, Möhler M, Büchler P, Klöppel G, Bitzer M, Endlicher E, Reinacher-Schick A, Heinemann V, Geissler M. 6597 Multicenter phase II trial of trastuzumab and capecitabine in patients with HER2 expressing metastasized pancreatic cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71318-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
Ebert MP, Auernhammer C, Caca K, Eckel F, Fischbach W, Geissler M, Göke B, Greten T, Kubicka S, Lutz MP, Möhler M, Opitz O, Pavel M, Porschen R, Reinacher-Schick A, Schmiegel W, Seufferlein T, Wiedenmann B, Schmid RM. [Gastrointestinal oncology - therapy update 2008 / 2009]. Z Gastroenterol 2009; 47:296-306. [PMID: 19267319 DOI: 10.1055/s-2008-1027989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
As a consequence of recent studies the treatment of gastrointestinal cancers has become challenging and is undergoing constant changes on the basis of the results of new trials. The steering committee of the working group on gastrointestinal cancers of the Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten has decided to summarise and present recent updates of the current treatment guidelines and recommendations for the most relevant gastrointestinal malignancies. In this review we have included recent findings from large trials on esophageal, gastric, pancreatic, cholangiocellular and liver cancers, as well as colorectal cancers, neuroendocrine tumours and lymphomas. This includes an update on the combination with novel targeted agents and the introduction of potential predictive biomarkers in the selection of the appropriate treatment strategy.
Collapse
Affiliation(s)
- M P Ebert
- II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, 81675 München.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Reinacher-Schick A, Arnold D, Lordick F, Möhler M, Lutz MP, Seufferlein T. [ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]. Z Gastroenterol 2006; 44:1065-72. [PMID: 17063436 DOI: 10.1055/s-2006-927142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review will give an overview on the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.
Collapse
Affiliation(s)
- A Reinacher-Schick
- Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
| | | | | | | | | | | |
Collapse
|
17
|
Eickhoff A, Martin W, Hartmann D, Eickhoff JC, Möhler M, Galle PR, Riemann JF, Jakobs R. A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma. Br J Cancer 2006; 94:1572-4. [PMID: 16721369 PMCID: PMC2361302 DOI: 10.1038/sj.bjc.6603174] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m−2 and EPI 45 mg m−2. Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
Collapse
Affiliation(s)
- A Eickhoff
- Medical Department C, Klinikum Ludwigshafen gGmbH, Bremserstr.79, Ludwigshafen D-67063, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Kaechele V, Seufferlein T, Höhler T, Möhler M, Lutz MP, Adler G. Oxaliplatin and paclitaxel in inoperable cancer of the esophagus and the gastro-esophogeal junction: Results of a phase I/II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V. Kaechele
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - T. Seufferlein
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - T. Höhler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - M. Möhler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - M. P. Lutz
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - G. Adler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| |
Collapse
|
19
|
Abstract
Over the last years the therapeutic possibilities for advanced gastric cancer have significantly increased. Here we discuss the new chemotherapeutic options and the existing results in palliative therapy.
Collapse
Affiliation(s)
- T Höhler
- 1. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz.
| | | |
Collapse
|
20
|
Möhler M, Siebler J, Hoehler T, Janssen J, Wein A, Menges M, Flieger D, Geer T, Galle P, Heike M. 214 Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90247-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
21
|
Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Möhler M, Oberdorfer F, van Kaick G. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39:1197-202. [PMID: 9669393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
UNLABELLED Prediction of chemotherapy response is still a problem in oncological patients. METHODS Studies with PET and 18F-fluorouracil (FU) were used for measurements of drug concentrations in patients with liver metastases from colorectal carcinoma. The PET data obtained before onset of FU chemotherapy were correlated to the growth rate of the metastases after therapy. The final evaluation included 25 metastases obtained in 17 patients. CT preceded the first chemotherapeutic cycle and was repeated within 3-11 mo after onset of treatment. The uptake of the cytostatic agent was evaluated in the liver metastases using the SUV at 120 min after tracer infusion. Tumor growth rate of the metastases was calculated based on CT volumetric data. RESULTS The trapping of 18F-FU was highly variable even for multiple metastases in the same patients. Six metastases with high 18F-FU uptake values exceeding 3.0 SUV correlated with negative growth rate values, 5 of 25 metastases with intermediate uptake values ranging from 2.0-3.0 SUV were associated with almost stable growth rate values nearly zero and 14 of 25 metastases with low uptake values <2.0 SUV demonstrated positive growth rate values. Only metastases with a 18F-FU uptake exceeding 3.0 SUV at 120 min postinjection demonstrated a response to therapy. A significant correlation of 0.86 (p < 0.001) was found between the 18F-FU uptake values in the metastases measured before chemotherapy and the growth rate of the lesions after treatment. CONCLUSION The data show, that FU chemotherapy outcome can be predicted using a single PET study with 18F-FU before onset to therapy.
Collapse
|
22
|
Affiliation(s)
- M Möhler
- Abteilung Innere Medizin IV, Universität Heidelberg
| | | | | |
Collapse
|
23
|
Möhler M, Kosa R, Maiwald M, Galle PR, Stremmel W. [43-year-old patient with undulating fever of unknown origin and abdominal symptoms]. Internist (Berl) 1998; 39:303-7. [PMID: 9561451 DOI: 10.1007/s001080050172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- M Möhler
- Abteilung Innere Medizin IV, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität, Heidelberg
| | | | | | | | | |
Collapse
|
24
|
Abstract
Little is known about the coincidence of hepatitis C virus infection (HCV) and non-Hodgkin's lymphoma, although there is an increased incidence of chronic HCV infection with cryoglobulinemia type II and, interestingly, low-grade non-Hodgkin's lymphoma (NHL) in a few patients. We therefore report on a 74-year-old white male with known chronic hepatitis C virus infection who was admitted to the clinic due to weight loss and pain in the right upper quadrant. Ultrasound examination was performed for suspected hepatocellular carcinoma since a lesion in the left lobe of the liver was seen. X-ray of the lungs showed a few scattered lesions, suggestive of metastases. The ultrasound-guided fine-needle puncture revealed a high-grade malignant B-cell NHL While alpha-fetoprotein was normal, both cryoglobulin type II and the polymerase chain reaction (PCR) for HCV were positive. After six cycles of chemotherapy consisting of CHOP, the patient showed complete remission over three years. Ultimately, he died due to a sudden myeloic blast crisis. In summary, we discuss the possible etiopathologic role of the hepatitis viruses in the occurrence of non-Hodgkin's lymphoma. As we and others showed that HCV infects peripheral mononuclear blood cells (PBML), the infected PBML not only may be a source for reinfection after orthotopic liver transplantation, but also could be the cause for transformation and monoclonal propagation of lymphomatous tissue.
Collapse
Affiliation(s)
- M Möhler
- Department of Gastroenterology, University of Heidelberg, Germany
| | | | | | | | | |
Collapse
|
25
|
Möhler M, Guzler F, Stremmel W. [Expression of the MRP gene coded conjugate transporter in human liver and its selective defect in canalicular membrane transport deficient rat hepatocytes]. Z Gastroenterol 1996; 34:296-7. [PMID: 8686362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
26
|
Möhler M, Gutzler F. [Administration of acetylsalicylic acid and risk of colorectal adenoma and carcinoma]. Z Gastroenterol 1995; 33:470-1. [PMID: 7483743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- M Möhler
- Abt. Innere Med. IV, Universität Heidelberg
| | | |
Collapse
|
27
|
Kleinschmidt JA, Möhler M, Weindler FW, Heilbronn R. Sequence elements of the adeno-associated virus rep gene required for suppression of herpes-simplex-virus-induced DNA amplification. Virology 1995; 206:254-62. [PMID: 7831779 DOI: 10.1016/s0042-6822(95)80040-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Herpes simplex virus (HSV) has been shown to induce DNA amplification in the host cell genome, which can be suppressed by the adeno-associated virus type 2 (AAV-2) rep gene (Heilbronn et al., 1990, J. Virol. 64, 3012-3018). In an attempt to define domains of Rep which are required for this effect a set of expression constructs was generated for Rep mutants with either N-terminal and/or C-terminal truncations, with small internal deletions, or with point mutations. In transient cotransfection assays these mutants were tested for the inhibition of HSV-induced DNA amplification and in parallel for DNA replication of a rep-defective AAV genome. Our data show that the C-terminal region of Rep where spliced and unspliced proteins differ is dispensable for both AAV DNA replication and inhibition of HSV-induced DNA amplification. The N-terminus of Rep is required for AAV DNA replication, whereas the first 174 amino acids can be deleted without loss of function for the inhibition of DNA amplification. Rep52 which starts at methionine 225 is neither sufficient, nor required for this effect. We further analyzed the region between amino acids 174 and 225: A stretch of 16 highly hydrophilic amino acids is dispensable for the inhibition of DNA amplification, but it is required for AAV DNA replication. Deletion of two short motifs spanning putative protein kinase C phosphorylation sites each strongly reduce both AAV DNA replication and inhibition of DNA amplification, whereas a single amino acid substitution of one of these sites abolished AAV DNA replication with no effect on the inhibition of DNA amplification. Our data show that most, but not all, of the sequence elements within the N-terminus of Rep78 required for AAV DNA replication coincide with those required for the inhibition of HSV-induced DNA amplification. A replication-negative version of Rep78 comprising the internal 60% of the protein still carry the entire inhibitory function for HSV-induced DNA amplification.
Collapse
|